Assoziation von Höhe der antipsychotischen Medikation über die Zeit mit Kognition unter Berücksichtigung des Geschlechts

Szuszies, Christoph Johannes

dc.contributor.advisor	Ehrenreich, Hannelore Prof. Dr. Dr.	de
dc.contributor.author	Szuszies, Christoph Johannes	de
dc.date.accessioned	2013-01-14T15:19:25Z	de
dc.date.available	2013-01-30T23:50:27Z	de
dc.date.issued	2012-06-04	de
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-000D-EFC2-B	de
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-1539
dc.format.mimetype	application/pdf	de
dc.language.iso	ger	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/	de
dc.title	Assoziation von Höhe der antipsychotischen Medikation über die Zeit mit Kognition unter Berücksichtigung des Geschlechts	de
dc.type	doctoralThesis	de
dc.title.translated	Association of antipsychotic dosage amount over time with cognition in schizophrenic patients in due consideration of gender	de
dc.contributor.referee	Ehrenreich, Hannelore Prof. Dr. Dr.	de
dc.date.examination	2012-06-06	de
dc.subject.dnb	610 Medizin, Gesundheit	de
dc.subject.gok	MED550	de
dc.description.abstracteng	Background: Available anti-psychotic drugs failed to show a positive effect on cognitive impairment, a core symptom of schizophrenic patients. Prescribing anti-psychotics is an essential part of patient treatment. Over the duration of treatment anti-psychotic daily doses are often escalated to an extreme, trying to alleviate symptoms. Sex-differences in the course of disease, symptoms of disease, cognition and sensitivity related to anti-psychotics are known. In contrast, the strength of cognitive impairment under increasing anti-psychotic dosage over time to very high anti-psychotic daily doses is not well-established. Methods: The association of anti-psychotic dosage amount over time with cognition in patients with schizophrenia in due consideration of sex in a widespread patient sample of n=1029 (GRAS- cross-sectional study) will be investigated for the first time. Approved psychometric and neurological rating scales, detailed neuropsychological tests, structured interviews, and evaluation of early health record concerning disease outbreak are background for the analyses. The value “dose-increase	de
dc.contributor.coReferee	Friede, Tim Prof. Dr.	de
dc.subject.topic	Medicine	de
dc.subject.ger	Schizophrenie	de
dc.subject.ger	Antipsychotika	de
dc.subject.ger	Kognition	de
dc.subject.ger	Krankheitsschwere	de
dc.subject.ger	Dosissteigerung	de
dc.subject.ger	Geschlecht	de
dc.subject.eng	schizophrenia	de
dc.subject.eng	antipsychotic therapy	de
dc.subject.eng	cognition	de
dc.subject.eng	disease severity	de
dc.subject.eng	dosage	de
dc.subject.eng	antipsychotics	de
dc.subject.eng	dose-increase	de
dc.subject.eng	gender	de
dc.subject.eng	sex	de
dc.subject.bk	44.91	de
dc.identifier.urn	urn:nbn:de:gbv:7-webdoc-3538-8	de
dc.identifier.purl	webdoc-3538	de
dc.affiliation.institute	Medizinische Fakultät	de
dc.identifier.ppn	730546985	de

Dateien

Name:szuszies.pdf

Größe:2.589Mb

Format:PDF

Öffnen

Name:: szuszies.pdf
Größe:: 2.589Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige